Molecular therapy intervention prospects in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Prostate cancer is a leading cause of cancer death in men, characterized by suppressed apoptosis rather than uncontrolled proliferation.
• Understanding the molecular mechanisms of apoptosis regulation is crucial for developing effective prostate cancer treatments.
• Molecularly targeting the suppression of apoptosis presents a promising therapeutic avenue for prostate cancer patients.

Purpose of the Study:

• To review key molecules involved in prostate cancer apoptosis regulation, including Bcl-2, Bcl-(XL), NF-kappaB, Akt, PTEN, and Par-4.
• To explore the therapeutic potential of targeting these molecules for both hormone-sensitive and hormone-resistant prostate cancer.
• To highlight the prospects of molecular therapy using tissue-specific promoters for targeted gene delivery.

Main Methods:

• Literature review of scientific articles focusing on prostate cancer, apoptosis, and molecular targets.
• Analysis of the roles of specific molecules (Bcl-2, Bcl-(XL), NF-kappaB, Akt, PTEN, Par-4) in prostate cancer progression.
• Evaluation of current and potential molecular therapeutic strategies for prostate cancer.

Main Results:

• Several key molecules (Bcl-2, Bcl-(XL), NF-kappaB, Akt, PTEN, Par-4) significantly influence prostate cancer cell apoptosis.
• Targeting these molecules offers potential for therapeutic intervention in prostate cancer.
• Molecular therapy, aided by tissue-specific promoters, shows promise for targeted gene delivery.

Conclusions:

• The suppression of apoptosis is a critical factor in prostate cancer progression.
• Targeting specific molecular pathways involved in apoptosis offers a viable strategy for prostate cancer treatment.
• Molecular therapy holds significant therapeutic potential for both hormone-sensitive and hormone-resistant prostate cancer.